Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer.

ABSTRACT:

Background

To investigate outcomes and morbidity of patients undergoing secondary cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent ovarian cancer.

Materials and methods

Between April 2014 and January 2019, a total of 51 recurrent ovarian cancer patients receiving secondary CRS and HIPEC were retrospectively reviewed.

Results

Among the 51 patients, median peritoneal cancer index score was 13 (range 3-34), and completeness of cytoreduction (CC) score of 0/1 was achieved in 41 patients (78.8%). Regimen of HIPEC included cisplatin and paclitaxel in 39 (75%) cases. The median follow-up duration of survivors was 20.2 months. Sixteen (30.8%) patients remained free of recurrence after HIPEC. The median progression-free survival (P

SUBMITTER: Chen WC 

PROVIDER: S-EPMC9661499 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature